CY1107468T1 - Καρβαμιδικες ενωσεις για χρηση στην προληψη ή την αγωγη διαταραχων του αγχους - Google Patents
Καρβαμιδικες ενωσεις για χρηση στην προληψη ή την αγωγη διαταραχων του αγχουςInfo
- Publication number
- CY1107468T1 CY1107468T1 CY20061100843T CY061100843T CY1107468T1 CY 1107468 T1 CY1107468 T1 CY 1107468T1 CY 20061100843 T CY20061100843 T CY 20061100843T CY 061100843 T CY061100843 T CY 061100843T CY 1107468 T1 CY1107468 T1 CY 1107468T1
- Authority
- CY
- Cyprus
- Prior art keywords
- group
- formula
- alkyl
- prevention
- treatment
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000003672 ureas Chemical class 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 150000001412 amines Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Η εφεύρεση αναφέρεται σε μία μέθοδο για την πρόληψη ή την αγωγή διαταραχών άγχους περιλαμβάνουσα τη χορήγηση σε ένα άτομο το οποίο την έχει ανάγκη μίας θεραπευτικά αποτελεσματικής ποσότητος μίας ενώσεως επιλεγόμενης από την ομάδα την αποτελούμενη από τον Τύπο (I) και τον Τύπο (II): Τύπος (I)· Τύπος (II)· όπου το φαινύλιο είναι υποκατασταθέν στο Χ με ένα έως πέντε άτομα αλογόνου επιλεγόμενα από την ομάδα την αποτελούμενη από φθόριο, χλώριο, βρώμιο και ιώδιο· και τα R1,R2, R3, R4, R5 και R6 επιλέγονται ανεξάρτητα από την ομάδα την αποτελούμενη από υδρογόνο και αλκύλιο με C1-C4· όπου το αλκύλιο με C1-C4 φέρει προαιρετικά υποκατάσταση με φαινύλιο (όπου το φαινύλιο φέρει προαιρετικά υποκατάσταση με υποκαταστάτες επιλεγόμενους ανεξάρτητα από την ομάδα την αποτελούμενη από αλογόνο, αλκύλιο με C1-C4, αλκοξύλιο με C1-C4, αμίνη, νιτροομάδα και κυάνιο).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168901P | 2001-02-27 | 2001-02-27 | |
| EP02759750A EP1399144B1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating anxiety disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107468T1 true CY1107468T1 (el) | 2012-12-19 |
Family
ID=23036639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061100843T CY1107468T1 (el) | 2001-02-27 | 2006-06-21 | Καρβαμιδικες ενωσεις για χρηση στην προληψη ή την αγωγη διαταραχων του αγχους |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7078436B2 (el) |
| EP (1) | EP1399144B1 (el) |
| JP (1) | JP2004523554A (el) |
| KR (1) | KR20030078947A (el) |
| CN (1) | CN1503665A (el) |
| AT (1) | ATE324107T1 (el) |
| AU (1) | AU2002306567B2 (el) |
| BR (1) | BR0207830A (el) |
| CA (1) | CA2439286A1 (el) |
| CY (1) | CY1107468T1 (el) |
| CZ (1) | CZ20032311A3 (el) |
| DE (1) | DE60210960T2 (el) |
| DK (1) | DK1399144T3 (el) |
| ES (1) | ES2262826T3 (el) |
| HU (1) | HUP0303262A2 (el) |
| IL (1) | IL157594A0 (el) |
| MX (1) | MXPA03007720A (el) |
| MY (1) | MY136391A (el) |
| NO (1) | NO20033800L (el) |
| NZ (1) | NZ546549A (el) |
| PL (1) | PL364639A1 (el) |
| PT (1) | PT1399144E (el) |
| RS (1) | RS50505B (el) |
| RU (1) | RU2292881C2 (el) |
| WO (1) | WO2002067923A1 (el) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004523554A (ja) * | 2001-02-27 | 2004-08-05 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 不安障害の予防もしくは治療における使用のためのカルバメート化合物 |
| JP2008528489A (ja) * | 2005-01-20 | 2008-07-31 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｑｔ間隔調節方法 |
| TWI419681B (zh) | 2005-06-08 | 2013-12-21 | Sk Biopharmaceuticals Co Ltd | 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途 |
| DE602007010818D1 (de) * | 2006-10-27 | 2011-01-05 | Janssen Pharmaceutica Nv | Verfahren zur behandlung disruptiver verhaltensstörungen |
| US8263652B2 (en) * | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| JP6131341B2 (ja) * | 2013-03-12 | 2017-05-17 | バイオ−ファーム ソリューションズ カンパニー リミテッド | フェニルカルバメート化合物及びこれを含む精神疾患の予防又は治療用組成物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄａｎｄａｃｏｍｐｏｓｉｔｉｏｎｆｏｒｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇａｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒｃｏｍｐｒｉｓｉｎｇｔｈｅｓａｍｅ｝ |
| CN109939092B (zh) * | 2013-03-12 | 2022-03-22 | 比皮艾思药物研发有限公司 | 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物 |
| BR112018067663B1 (pt) | 2016-02-29 | 2023-01-10 | Bio-Pharm Solutions Co., Ltd | Compostos derivados de sulfamato, seus usos e composição farmacêutica |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| US10959976B2 (en) | 2017-06-02 | 2021-03-30 | Jazz Pharmaceuticals Ireland Limited | Methods and compositions for treating excessive sleepiness |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3278380A (en) * | 1962-02-06 | 1966-10-11 | Armour Pharma | Methods of calming employing diphenyl hydroxy carbamate compounds |
| US3248418A (en) | 1962-06-26 | 1966-04-26 | Charles D Bossinger | 2-hydroxy-2-phenyl alkyl carbamates |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| CN1109880A (zh) * | 1994-02-03 | 1995-10-11 | 合成实验室公司 | 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用 |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| DK1408953T3 (da) | 2001-02-27 | 2006-08-21 | Ortho Mcneil Pharm Inc | Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom |
| AU2002242296B2 (en) | 2001-02-27 | 2006-06-29 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating psychotic disorders |
| JP2004523554A (ja) * | 2001-02-27 | 2004-08-05 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 不安障害の予防もしくは治療における使用のためのカルバメート化合物 |
-
2002
- 2002-02-21 JP JP2002567290A patent/JP2004523554A/ja active Pending
- 2002-02-21 DK DK02759750T patent/DK1399144T3/da active
- 2002-02-21 NZ NZ546549A patent/NZ546549A/en not_active IP Right Cessation
- 2002-02-21 RS YUP-679/03A patent/RS50505B/sr unknown
- 2002-02-21 BR BR0207830-9A patent/BR0207830A/pt not_active IP Right Cessation
- 2002-02-21 AT AT02759750T patent/ATE324107T1/de active
- 2002-02-21 IL IL15759402A patent/IL157594A0/xx unknown
- 2002-02-21 EP EP02759750A patent/EP1399144B1/en not_active Expired - Lifetime
- 2002-02-21 HU HU0303262A patent/HUP0303262A2/hu unknown
- 2002-02-21 KR KR10-2003-7011293A patent/KR20030078947A/ko not_active Ceased
- 2002-02-21 US US10/081,713 patent/US7078436B2/en not_active Expired - Fee Related
- 2002-02-21 CN CNA028087143A patent/CN1503665A/zh active Pending
- 2002-02-21 WO PCT/US2002/005423 patent/WO2002067923A1/en active IP Right Grant
- 2002-02-21 CA CA002439286A patent/CA2439286A1/en not_active Abandoned
- 2002-02-21 RU RU2003128986/14A patent/RU2292881C2/ru not_active IP Right Cessation
- 2002-02-21 MX MXPA03007720A patent/MXPA03007720A/es active IP Right Grant
- 2002-02-21 PL PL02364639A patent/PL364639A1/xx not_active Application Discontinuation
- 2002-02-21 PT PT02759750T patent/PT1399144E/pt unknown
- 2002-02-21 DE DE60210960T patent/DE60210960T2/de not_active Expired - Lifetime
- 2002-02-21 AU AU2002306567A patent/AU2002306567B2/en not_active Ceased
- 2002-02-21 CZ CZ20032311A patent/CZ20032311A3/cs unknown
- 2002-02-21 ES ES02759750T patent/ES2262826T3/es not_active Expired - Lifetime
- 2002-02-27 MY MYPI20020693A patent/MY136391A/en unknown
-
2003
- 2003-08-26 NO NO20033800A patent/NO20033800L/no not_active Application Discontinuation
-
2005
- 2005-08-01 US US11/194,251 patent/US20050267203A1/en not_active Abandoned
-
2006
- 2006-06-21 CY CY20061100843T patent/CY1107468T1/el unknown
-
2009
- 2009-06-01 US US12/475,815 patent/US20090234003A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MY136391A (en) | 2008-09-30 |
| CZ20032311A3 (cs) | 2005-02-16 |
| US7078436B2 (en) | 2006-07-18 |
| RU2292881C2 (ru) | 2007-02-10 |
| US20050267203A1 (en) | 2005-12-01 |
| JP2004523554A (ja) | 2004-08-05 |
| BR0207830A (pt) | 2004-06-22 |
| NO20033800D0 (no) | 2003-08-26 |
| RS50505B (sr) | 2010-03-02 |
| IL157594A0 (en) | 2004-03-28 |
| PT1399144E (pt) | 2006-07-31 |
| EP1399144B1 (en) | 2006-04-26 |
| YU67903A (sh) | 2006-08-17 |
| NZ546549A (en) | 2007-11-30 |
| DE60210960D1 (de) | 2006-06-01 |
| DE60210960T2 (de) | 2006-11-16 |
| PL364639A1 (en) | 2004-12-13 |
| CN1503665A (zh) | 2004-06-09 |
| US20020143053A1 (en) | 2002-10-03 |
| RU2003128986A (ru) | 2005-03-20 |
| HUP0303262A2 (hu) | 2004-01-28 |
| DK1399144T3 (da) | 2006-07-24 |
| CA2439286A1 (en) | 2002-09-06 |
| HK1062270A1 (en) | 2004-10-29 |
| AU2002306567B2 (en) | 2006-08-17 |
| KR20030078947A (ko) | 2003-10-08 |
| MXPA03007720A (es) | 2004-11-12 |
| WO2002067923A1 (en) | 2002-09-06 |
| ATE324107T1 (de) | 2006-05-15 |
| US20090234003A1 (en) | 2009-09-17 |
| ES2262826T3 (es) | 2006-12-01 |
| NO20033800L (no) | 2003-09-26 |
| EP1399144A1 (en) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107468T1 (el) | Καρβαμιδικες ενωσεις για χρηση στην προληψη ή την αγωγη διαταραχων του αγχους | |
| CY1105330T1 (el) | Καρβαμιδικα παραγωγα για χρηση στην προληψη ή την αγωγη της διπολικης διαταραχης | |
| CY1106924T1 (el) | Ενωσεις καρβαμικου για χρηση οσον αφορα την προληψη ή την αγωγη των διαταραχων κινησης | |
| CY1111349T1 (el) | Καρβαμιδικες ενωσεις προς χρηση στη θεραπεια του πονου | |
| CY1106753T1 (el) | Καρβαμιδικαι ενωσεις δια χρησιν εις προληψιν ή νοσηλειαν νευροεκφυλιστικων διαταραχων | |
| CY1107199T1 (el) | Καρβαμικες ενωσεις για χρηση στη προληψη ή τη θεραπευτικη αντιμετωπιση της διπολικης διαταραχης | |
| CY1116119T1 (el) | Παραγωγα ισοξαζολο-πυριδινης | |
| NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
| RS67503A (en) | Carbamate compounds for use in preventing of treating psychotic disorders | |
| CY1109429T1 (el) | Καρβαμιδικες ενωσεις για χρηση στην προληψη ή τη θεραπεια του πονου λογω νευροπαθειας | |
| CY1106038T1 (el) | Καρβαμικες ενωσεις για χρηση στην προληψη ή την αγωγη του νeυpοπαθους πονου και του πονου που συνδεεται με την ισταμινογενη κεφαλαλγια και την ημικρανια | |
| CY1110672T1 (el) | Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders |